(Q35764572)

10 August 2017

1 reference

title

Circulating tumour markers in breast cancer (English)

1 reference

10 August 2017

Ettore Seregni

1

1 reference

10 August 2017

Antonio Coli

series ordinal

2

1 reference

10 August 2017

Nicola Mazzucca

series ordinal

3

1 reference

10 August 2017

Italian Group RIA-IRMA Test, Italian Association of Nuclear Medicine

series ordinal

4

1 reference

10 August 2017

4 May 2004

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

10 August 2017

1 reference

10 August 2017

31 Suppl 1

1 reference

10 August 2017

S15-22

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-004-1523-z

10 August 2017

0 references

cites work

American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines.

1 reference

12 December 2020

Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane

1 reference

12 December 2020

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer

1 reference

12 December 2020

Circulating tumor markers in breast cancer: accepted utilities and novel prospects

1 reference

12 December 2020

Practice guidelines for tumor marker use in the clinic.

1 reference

12 December 2020

Cloning of a carcinoembryonic antigen gene family member expressed in leukocytes of chronic myeloid leukemia patients and bone marrow

1 reference

12 December 2020

CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases

1 reference

12 December 2020

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

1 reference

12 December 2020

CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases

1 reference

12 December 2020

Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases

1 reference

12 December 2020

Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation.

1 reference

12 December 2020

Proteomic applications for the early detection of cancer

1 reference

12 December 2020

Human MUC1 mucin: a potent glandular morphogen

1 reference

12 December 2020

Intermediate filaments: a review of the basic biology.

1 reference

12 December 2020

Relationship between plasma carcinoembryonic antigen and prognosis in women with breast cancer

1 reference

12 December 2020

Suppression of cellular aggregation by high levels of episialin

1 reference

12 December 2020

Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer

1 reference

12 December 2020

Prognostic significance of CEA in breast cancer: a statistical study

1 reference

12 December 2020

C-erbB2 oncoprotein and its soluble ectodomain: a new potential tumor marker for prognosis early detection and monitoring patients undergoing Herceptin treatment

1 reference

12 December 2020

Cytokeratins and tissue polypeptide antigen.

1 reference

12 December 2020

MUC1: antibodies and immunoassays

1 reference

12 December 2020

Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game

1 reference

12 December 2020

Structural effects of O-glycosylation on a 15-residue peptide from the mucin (MUC1) core protein

1 reference

12 December 2020

Carcino-embryonic antigen assay as a guide to tumour bulk, response to therapy and prognosis in human breast cancer

1 reference

12 December 2020

Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland

1 reference

12 December 2020

Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.

1 reference

12 December 2020

Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study

1 reference

12 December 2020

Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: special emphasis on "spiking" phenomena

1 reference

12 December 2020

A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA

1 reference

12 December 2020

Human MUC1 mucin: a multifaceted glycoprotein.

1 reference

12 December 2020

A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study

1 reference

12 December 2020

Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer

1 reference

12 December 2020

Binding of tumor antigen mucin (MUC1) derived peptides to the heat shock protein DnaK

1 reference

12 December 2020

DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES

1 reference

12 December 2020

Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation

1 reference

12 December 2020

Tumour marker measurements in the diagnosis and monitoring of breast cancer.

1 reference

12 December 2020

Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.

1 reference

12 December 2020

Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy.

1 reference

12 December 2020

Molecular and cellular biology of intermediate filaments

1 reference

12 December 2020

CA 15-3: a prognostic marker in breast cancer.

1 reference

12 December 2020

Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients

1 reference

12 December 2020

Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?

1 reference

12 December 2020

Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity

1 reference

12 December 2020

Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer

1 reference

12 December 2020

Cytokeratins in the histological diagnosis of malignant tumors

1 reference

12 December 2020

Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule

1 reference

12 December 2020

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress

1 reference

12 December 2020

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

1 reference

12 December 2020

Prognostic value of CEA and ferritin assay in breast cancer: a multivariate analysis

1 reference

12 December 2020

Biochemical markers in breast cancer: which ones are clinically useful?

1 reference

12 December 2020

HER-2/neu as a predictive marker of response to breast cancer therapy

1 reference

12 December 2020

Phosphorylation of the cytoplasmic domain of the MUC1 mucin correlates with changes in cell-cell adhesion

1 reference

12 December 2020

Ca 15-3 in the follow-up of localised breast cancer: a prospective study

1 reference

12 December 2020

1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology

1 reference

12 December 2020

Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma

1 reference

12 December 2020

Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients

1 reference

12 December 2020

The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin

1 reference

12 December 2020

New immunoassays for MUC1 in breast cancer

1 reference

12 December 2020

Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma

1 reference

12 December 2020

Serum CEA and CA 15-3 as prognostic factors in primary breast cancer

1 reference

12 December 2020

Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology

1 reference

12 December 2020

Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors.

1 reference

12 December 2020

The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19

1 reference

12 December 2020

Functional relationship and gene ontology classification of breast cancer biomarkers

1 reference

12 December 2020

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers

1 reference

12 December 2020

Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.

1 reference

12 December 2020

10.1007/S00259-004-1523-Z

Identifiers

DOI

1 reference

10 August 2017

1 reference